Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca drops durvalumab early approval plan

AstraZeneca has given up on the idea of seeking early approval of its immunotherapy drug durvalumab in head & neck cancer using mid-stage Phase II trials data.

Read More »

Pfizer wins EU approval for Ibrance as Novartis readies rival drug

Pfizer won approval from the European Union for its best-selling breast cancer drug Ibrance, making it the first medicine of its kind to reach the European market.

Read More »

Pfizer to Shutter Two UK Facilities and Lay Off 370 Over Four Years

Pfizer announced that the company will be closing two of its three facilities in the UK. The facilities will close over the next four years, and affect approximately 370 jobs.

Read More »

3 Pharmas Relying on Innovation, Not Drug Price Increases for Growth

With some uncertainty facing the biotech and pharma industry following the election of Donald Trump as the next president of the United States, investors should focus on companies that rely on innovation rather than price increases.

Read More »

Arrowhead Hep B Study Placed on Clinical Hold

Shares of Arrowhead Pharmaceuticals were down after the company’s experimental hepatitis B drug, ARC-520, was placed on clinical hold by the U.S. FDA.

Read More »

Biotech, Pharma Stocks Jump after Trump Victory

The reality of a President-elect Donald Trump has been a shot in the arm for pharma and biotech leaders’ stock prices as they surged in U.S. and European markets.

Read More »

San Francisco passes soda tax, other cities on track to approve

Voters in San Francisco passed a tax on sugar-sweetened beverages, unofficial results showed, as the push by local governments to target soda to stem obesity and diabetes gathered speed.

Read More »

California drug pricing initiative headed for defeat

A California ballot initiative aimed at reining in rising prices for prescription drugs was headed for defeat after pharmaceutical companies spent more than $100 million to fight it.

Read More »

How Pharma Can Continue Moving Beyond the Pill

It’s important for the pharma industry to take a closer look at the benefits of going beyond the pill and leveraging technology to deliver better care resulting in better patient outcomes and potential savings to the overall health system.

Read More »

U.S. watchdog told Medicare, Medicaid that EpiPen was misclassified in 2009: senator

The internal watchdog at the U.S. Department of Health and Human Services warned the office tasked with administering federal health insurance programs that Mylan NV’s EpiPen was improperly classified as a generic drug in 2009, Senator Charles Grassley said.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom